Consistent with the mouse results, we found that HER2+ BC patients with a highly activated pd16HER2D/pSRC signaling axis, which was molecularly identified by the presence of a genomic profile characterized by the significant enrichment of gene pathways related to hypoxia, tumor metastasis and cell motility (termed activated d16HER2 metagene), derived the greatest benefit from trastuzumab treatment [37]. This evidence concerns the gene ERBB2 and neoplasm.